Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Apr 1;28(4):702-710.
doi: 10.1093/annonc/mdx010.

Fifth Ovarian Cancer Consensus Conference: individualized therapy and patient factors

J McGee  1 , M Bookman  2 , P Harter  3 , C Marth  4 , I McNeish  5 , K N Moore  2 , A Poveda  6 , F Hilpert  3 , K Hasegawa  7 , M Bacon  8 , C Gatsonis  9 , A Brand  10 , F Kridelka  11 , J Berek  12 , N Ottevanger  13 , T Levy  14 , S Silverberg  15 , B-G Kim  16 , H Hirte  1 , A Okamoto  15 , G Stuart  1 , K Ochiai  15 ; participants of the 5th Ovarian Cancer Consensus Conference
Affiliations
Free article

Fifth Ovarian Cancer Consensus Conference: individualized therapy and patient factors

J McGee et al. Ann Oncol. .
Free article

Abstract

This manuscript reports the consensus statements regarding the design and conduct of clinical trials in patients with newly diagnosed and recurrent epithelial ovarian cancer (EOC), following deliberation at the Fifth Ovarian Cancer Consensus Conference (OCCC), held in Tokyo in November 2015. Three important questions were identified for discussion prior to the meeting and achieved consensus during the meeting: (i) What are the most important factors to be evaluated prior to initial therapy? (ii) What are the most important factors to be evaluated specifically in recurrent disease? (iii) Are there specific considerations for special patient subpopulations? In addition, we report a list of important unmet needs compiled during the consensus process, which is intended to guide future research initiatives.

Keywords: GCIG; consensus conference; individualized therapy; ovarian cancer; recommendations.

PubMed Disclaimer

Publication types